[
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352266",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352267",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352268",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352269",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352270",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": null,
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No Recommendation.",
        "drugrecommendation_short": "No Recommendation.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352271",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352272",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352273",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352274",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352275",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": null,
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No Recommendation.",
        "drugrecommendation_short": "No Recommendation.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352343",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352276",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352277",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352278",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352279",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352280",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352281",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352282",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": null,
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No Recommendation.",
        "drugrecommendation_short": "No Recommendation.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352283",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "No Result"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352284",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "No Result",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "No Result"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "No Result"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352285",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "No Result",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "No Result"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352286",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352287",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352288",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352289",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352290",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": null,
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No Recommendation.",
        "drugrecommendation_short": "No Recommendation.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352291",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352292",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352293",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352294",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352295",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352296",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352297",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352298",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352299",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352300",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352301",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352302",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": null,
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No Recommendation.",
        "drugrecommendation_short": "No Recommendation.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352303",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "No Result"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352304",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "No Result",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "No Result"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "No Result"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "phenytoin"
        },
        "drugid": "RxNorm:8183",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352305",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "No Result",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "No Result"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352306",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352307",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352308",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352309",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352310",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": null,
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No Recommendation.",
        "drugrecommendation_short": "No Recommendation.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352311",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352312",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352313",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352314",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352315",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352316",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352317",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352318",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352319",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352320",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "No Result"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352344",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "No Result",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "No Result"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352321",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352322",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": null,
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No Recommendation.",
        "drugrecommendation_short": "No Recommendation.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352323",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "No Result"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352324",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "No Result",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "No Result"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "No Result"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Strong",
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "drugrecommendation_short": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352325",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "No Result",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "No Result"
        },
        "population": "PHT naive",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352326",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352327",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352328",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352329",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352330",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 negative"
        },
        "classification": null,
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No Recommendation.",
        "drugrecommendation_short": "No Recommendation.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352331",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "*15:02 negative"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352332",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352333",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352334",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352335",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352336",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "n/a"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352337",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "n/a",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "Indeterminate"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "2.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352338",
        "implications": {
            "CYP2C9": "Normal phenytoin metabolism",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "2",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Normal Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.5"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "No adjustments needed from typical dosing strategies.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352339",
        "implications": {
            "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1.5",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "1.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352340",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "1",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.5"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352341",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0.5",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "0.0"
        },
        "allelestatus": {
            "HLA-B": "No HLA-B Result"
        },
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "drugrecommendation_short": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352342",
        "implications": {
            "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.",
            "HLA-B": "n/a"
        },
        "lookupkey": {
            "CYP2C9": "0",
            "HLA-B": "No Result"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "population": "PHT use >3mos",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C9": "No Result"
        },
        "allelestatus": {
            "HLA-B": "HLA-B*15:02 positive"
        },
        "classification": "Optional",
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "drug": {
            "name": "fosphenytoin"
        },
        "drugid": "RxNorm:72236",
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "drugrecommendation_short": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",
        "guideline": {
            "name": "CYP2C9, HLA-B and Phenytoin"
        },
        "guidelineid": "100412",
        "id": "1352345",
        "implications": {
            "CYP2C9": "n/a",
            "HLA-B": "Increased risk of phenytoin-induced SJS/TEN"
        },
        "lookupkey": {
            "CYP2C9": "No Result",
            "HLA-B": "*15:02 positive"
        },
        "phenotypes": {
            "CYP2C9": "No Result"
        },
        "population": "PHT use >3mos",
        "version": "1"
    }
]